Breaking News

Cingulate Successfully Transfers CTx-1301 PTR Manufacturing Processes to Societal CDMO

Societal CDMO has successfully completed the construction of a manufacturing suite outfitted with equipment supplied by Cingulate.

Cingulate Inc., a biopharmaceutical company utilizing its Precision Timed Release (PTR) drug delivery platform technology to advance a pipeline of next-generation pharmaceuticals, announced the successful completion of the manufacturing transfer of its lead candidate, CTx-1301 (dexmethylphenidate), to Societal CDMO, a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters